Skip to main content
Yingbin Liu on Muck Rack

Yingbin Liu

As seen in: Nature, Wiley Online Library, ScienceDirect, Frontiers, MDPI, Taylor & Francis Online, ACS Publications, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingbin

Contact Yingbin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bacteroides fragilis toxin promotes gall bladder cancer in mice

|
By jun chen, Siyuan Kang, Haoyan Liu, Peng Pu, Xiaoling Song, Yingbin Liu, Jingjing Qi, Wenguang Wu, Aiyanlun Tong, Zisong Xu
| Nature Verified
Abstract Enterotoxigenic Bacteroides fragilis (ETBF), which secretes B. fragilis toxin (BFT) and has been associated with colorectal cancer, can be enriched in patients with gall bladder cancer (GBC). Whether and how ETBF contributes to GBC is unclear. Here we confirm, through analysis of patient samples, that ETBF is enriched in GBC tumours, while experiments in mice show that ETBF colonizes the gall bladder. In vitro and in patient-derived organoids, ETBF promoted GBC proliferation.
Open in Who Shared Issue with article?

Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling

|
By Huanhuan Zhang, Ruolan Wang, Pan Shi, Qingjun Zhu, Xinheng He, Youwei Xu, Qingning Yuan, Wen Hu, Kai Wu, Yong Zheng, Li Zhou Verified, Jun Liang, Pei Lv, Ziyan Xu, Fan Yang, Yingbin Liu, Youwen Zhuang, H. Xu, YUE WANG, Changlin Tian, Gaoming Wang
| Nature Verified
Abstract Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y3207.43 as a key residue that is critical for signaling bias.
Open in Who Shared Issue with article?

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial

|
By Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Yongmei Yin, Min-Hee Ryu, John Park, Shusuan Jiang, Jee Hyun Kim, Shouman Wang, Yahua Zhong, Mark Voskoboynik, Jian Zhang, Andreas Kaubisch, Caigang Liu, Yu Chen, Seock-Ah Im, Lingying Wu, Yingbin Liu, Vinod Ganju, Minal Barve, Hui Li, Guangyu Yao, Lequn Bao, Yiming Zhao Verified, Jianli Zhao, Yu Shen, Xiaoyu Zhu, Erwei Song, Mudan Yang, Kaijing Zhao, Shangyi Rong
| Nature Verified
Abstract SHR-A1811, an antibody‒drug conjugate consisting of the anti-HER2 antibody trastuzumab conjugated via a cleavable linker to a topoisomerase I inhibitor payload, demonstrated substantial antitumor activity in patients with heavily treated HER2-expressing or mutated advanced solid tumors. The main analysis was reported, and this is a long-term follow-up of the HORIZON-X trial (NCT04446260).
Open in Who Shared Issue with article?
See all 13 articles